Takaaki Nakashima1,2, Takeshi Nonoshita2, Hidenari Hirata3, Kouji Inoue4, Akira Nagashima5, Tadamasa Yoshitake3, Kaori Asai3, Yoshiyuki Shioyama3. 1. Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan takaaki813@hotmail.co.jp. 2. Department of Radiology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan. 3. Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 4. Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan. 5. Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Abstract
BACKGROUND: We investigated acute adverse events in patients with brain metastases (BMs) of anaplastic lymphoma kinase-rearranged (ALKr) non-small cell lung cancer (NSCLC) treated with both cranial radiotherapy and tyrosine kinase inhibitors (TKIs) of ALK. PATIENTS AND METHODS: Acute AEs were retrospectively investigated in patients with BMs of ALKr-NSCLC who received both whole-brain radiotherapy (WBRT) and ALK-TKI. For comparison, they were also assessed in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and wild-type with neither ALK rearrangement nor EGFR mutation treated with WBRT. RESULTS: Two ALKr cases were consequently eligible. Grade 3 otitis media unexpectedly occurred in both cases, while there was one case out of 11 and one case out of 18 of grade 2 otitis media among the EGFR-mutated cases and wild-type cases (p=0.013), respectively. CONCLUSION: Concurrent treatment with WBRT and ALK-TKI may be associated with acute severe ear toxicity in patients with BMs of ALKr-NSCLC. Copyright
BACKGROUND: We investigated acute adverse events in patients with brain metastases (BMs) of anaplastic lymphoma kinase-rearranged (ALKr) non-small cell lung cancer (NSCLC) treated with both cranial radiotherapy and tyrosine kinase inhibitors (TKIs) of ALK. PATIENTS AND METHODS: Acute AEs were retrospectively investigated in patients with BMs of ALKr-NSCLC who received both whole-brain radiotherapy (WBRT) and ALK-TKI. For comparison, they were also assessed in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and wild-type with neither ALK rearrangement nor EGFR mutation treated with WBRT. RESULTS: Two ALKr cases were consequently eligible. Grade 3 otitis media unexpectedly occurred in both cases, while there was one case out of 11 and one case out of 18 of grade 2 otitis media among the EGFR-mutated cases and wild-type cases (p=0.013), respectively. CONCLUSION: Concurrent treatment with WBRT and ALK-TKI may be associated with acute severe ear toxicity in patients with BMs of ALKr-NSCLC. Copyright
Authors: Gary V Walker; Salmaan Ahmed; Pamela Allen; Paul W Gidley; Shiao Y Woo; Franco DeMonte; Eric L Chang; Anita Mahajan Journal: Int J Radiat Oncol Biol Phys Date: 2011-01-27 Impact factor: 7.038
Authors: Maarten Lambrecht; Daniëlle B P Eekers; Claire Alapetite; Neil G Burnet; Valentin Calugaru; Ida E M Coremans; Piero Fossati; Morten Høyer; Johannes A Langendijk; Alejandra Méndez Romero; Frank Paulsen; Ana Perpar; Laurette Renard; Dirk de Ruysscher; Beate Timmermann; Pavel Vitek; Damien C Weber; Hiske L van der Weide; Gillian A Whitfield; Ruud Wiggenraad; Erik Roelofs; Petra Witt Nyström; Esther G C Troost Journal: Radiother Oncol Date: 2018-05-17 Impact factor: 6.280
Authors: Kimberly L Johung; Norman Yeh; Neil B Desai; Terence M Williams; Tim Lautenschlaeger; Nils D Arvold; Matthew S Ning; Albert Attia; Christine M Lovly; Sarah Goldberg; Kathryn Beal; James B Yu; Brian D Kavanagh; Veronica L Chiang; D Ross Camidge; Joseph N Contessa Journal: J Clin Oncol Date: 2015-10-05 Impact factor: 44.544
Authors: Paul W Sperduto; Norbert Kased; David Roberge; Zhiyuan Xu; Ryan Shanley; Xianghua Luo; Penny K Sneed; Samuel T Chao; Robert J Weil; John Suh; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Siow Ming Lee; Conrad R Lewanski; Nicholas Counsell; Christian Ottensmeier; Andrew Bates; Nirali Patel; Christina Wadsworth; Yenting Ngai; Allan Hackshaw; Corinne Faivre-Finn Journal: J Natl Cancer Inst Date: 2014-07-16 Impact factor: 13.506